The financial reports of the top 12 listed instrum

The financial reports of 12 listed instrument companies let you know the income brought by the COVID-19 to instrument enterprises

the COVID-19 is spreading all over the world, which is both a challenge and an opportunity for instrument enterprises. The supply and demand problems caused by the epidemic are transmitted along the upstream and downstream of the industrial chain, and the shift speed of traditional analytical instruments in the market is reduced, but the demand for equipment and consumables involved in the epidemic, such as diagnosis, vaccine and drug development, viral pathology research, has surged

in August, the semi annual financial reports of domestic and foreign listed instrument companies have been released one after another. How much revenue will COVID-19 bring to instrument enterprises and how much impact will it have on the business of traditional analytical instruments? By reading the financial statements of 12 listed instrument companies, we try to find some clues from the measured experimental data, which can be shared with the majority of readers

(2) regular oil change list of the first half revenue of six foreign instrument enterprises

Thermo Fisher

the second quarter revenue of the life science solutions department was $2.6 billion, an increase of 52% year-on-year; The revenue related to COVID-19 is about 1.3 billion US dollars; The revenue of the analytical instrument department fell by 20% year-on-year in this quarter. The newly developed covid-19 reagent product has been extended by the emergency use authorization (EUA), which can run Thermo Fisher PCR tests on other instruments and consumables; A new plant was designed and built in lenecksa, Kansas, to produce highly specialized virus transport media (VTM) for sample collection under U.S. government contracts; Cooperate with Wuxi diagnostics and Mayo Clinic to develop total antibody serological tests; Signed a multi-year pharmaceutical service contract with the US biomedical advanced research and Development Administration (BARDA) to support the acceleration of vaccine development and production...

Danaher

in the second quarter, the life science business revenue accounted for 49.8% of the total revenue, which was $2.64 billion, an increase of 54.3% year-on-year over the same period last year. SCIEX and Leica Microsystems, where the mass spectrometry business is located, both fell in the second quarter. Beckman Kurt life sciences company launched a new RNA extraction kit that has been verified to be used for real-time PCR virus research of infectious diseases and pathogens. Saipei xpert Xpress sars-cov-2 nucleic acid detection reagent was authorized by the U.S. Food and Drug Administration for emergency use (FDA EUA) for qualitative detection of covid-19 nucleic acid. More than 6million kits were delivered in the second quarter. Saipei has developed a rapid four in one test method to detect covid-19, influenza A, influenza B and respiratory syncytial virus from a single patient sample. The test is expected to start in the third quarter. Due to the demand for covid-19 test, the core revenue of Saipei increased by more than 100% year-on-year

Roche Diagnostics

molecular diagnostics business revenue was 1.558 billion Swiss francs (US $1.7 billion), with a year-on-year revenue of +51% (calculated at a fixed exchange rate of +61%), accounting for 26% of the total diagnostic revenue, which was the strongest driving force for the growth of Roche Diagnostics business in the first half of the year. During the outbreak of novel coronavirus, the Cobas sars-cov-2 test reagent developed by Roche for covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid. In May, in order to further deepen the strategic layout of Roche Diagnostics in China, Roche announced that it would further increase investment in its Roche Diagnostics Asia Pacific production base and R & D center located in Suzhou Industrial Park, with a total planned new investment of US $180million and a total cumulative investment of US $479million

its covid-19 detection products appeared at the White House press conference for many times. From the sorting of public information, Abbott's molecular diagnosis business had a revenue of 498million US dollars in the first half of the year, an increase of +131.1% year-on-year; The POC business revenue from the acquisition of alere was $1.09 billion, a year-on-year increase of +6.8%, which was mainly due to the new crown detection products of ID now platform

Siemens Healthcare

the revenue of Siemens' medical diagnosis business in the first half of 2020 was $2.312 billion, with a year-on-year increase of +2%, mainly driven by the U.S. market. The Chinese market is still growing relatively, with a revenue of 923 million euros, with a year-on-year increase of +10%. Its covid-19 detection kit is the fast track diagnostics (FTD) sars-cov-2 analysis and detection kit

Perkin Elmer

revenue related to COVID-19 was $196million in the second quarter. In this quarter, the organic revenue of diagnosis increased by 48%, and the organic revenue of exploration and analysis solutions business decreased by 10%. Non covid-19 sales naturally fell by 14% year-on-year, and non covid-19 diagnostic revenue fell by 20%

the novel coronavirus nucleic acid detection kit (RT-PCR) developed by the company was approved by the U.S. Food and Drug Administration (FDA) in March. Based on PCR detection, RNA extraction solutions and serology kits, the company has driven the sales of covid-19 related diagnostics. Each contributed more than $50million in revenue in the second quarter. Perkin Elmer is also actively studying other technologies for direct detection of covid-19, including instant testing and ELISA based antigen detection. The company is focusing on the simultaneous detection system of novel coronavirus and influenza, and hopes to commercialize the detection product before the beginning of the autumn flu season

list of the first half revenue of six domestic instrument enterprises

Thermo Fisher

the second quarter revenue of the life science solutions department was $2.6 billion, an increase of 52% year-on-year; The revenue related to COVID-19 is about 1.3 billion US dollars; The revenue of the analytical instrument department fell by 20% year-on-year in this quarter. The newly developed covid-19 reagent product has been extended by the emergency use authorization (EUA), which can run Thermo Fisher PCR tests on other instruments and consumables; A new plant was designed and built in lenecksa, Kansas, to produce highly specialized virus transport media (VTM) for sample collection under U.S. government contracts; Cooperate with Wuxi diagnostics and Mayo Clinic to develop total antibody serological tests; Signed a multi-year pharmaceutical service contract with the US biomedical advanced research and Development Administration (BARDA) to support the acceleration of vaccine development and production...

Danaher

in the second quarter, the life science business revenue accounted for 49.8% of the total revenue, which was $2.64 billion, an increase of 54.3% year-on-year over the same period last year. SCIEX and Leica Microsystems, where the mass spectrometry business is located, both fell in the second quarter. Beckman Kurt life sciences company launched a new RNA extraction kit that has been verified to be used for real-time PCR virus research of infectious diseases and pathogens. Saipei xpert Xpress sars-cov-2 nucleic acid detection reagent was authorized by the U.S. Food and Drug Administration for emergency use (FDA EUA) for qualitative detection of covid-19 nucleic acid. More than 6million kits were delivered in the second quarter. Saipei has developed a rapid four in one test method to detect covid-19, influenza A, influenza B and respiratory syncytial virus from a single patient sample. The test is expected to start in the third quarter. Due to the demand for covid-19 test, the core revenue of Saipei increased by more than 100% year-on-year

Roche Diagnostics

molecular diagnostics business revenue was 1.558 billion Swiss francs (US $1.7 billion), with a year-on-year revenue of +51% (calculated at a fixed exchange rate of +61%), accounting for 26% of the total diagnostic revenue, which was the strongest driving force for the growth of Roche Diagnostics business in the first half of the year. During the outbreak of novel coronavirus, the Cobas sars-cov-2 test reagent developed by Roche for covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid-covid. In May, in order to further deepen the strategic layout of Roche Diagnostics in China, Roche announced that it would further increase investment in its Roche Diagnostics Asia Pacific production base and R & D center located in Suzhou Industrial Park, with a total planned new investment of US $180million and a total cumulative investment of US $479million

its covid-19 detection products appeared at the White House press conference for many times. From the sorting of public information, Abbott's molecular diagnosis business had a revenue of 498million US dollars in the first half of the year, an increase of +131.1% year-on-year; The POC business revenue from the acquisition of alere was $1.09 billion, a year-on-year increase of +6.8%, which was mainly due to the new crown detection products of ID now platform

Siemens Healthcare

the revenue of Siemens' medical diagnosis business in the first half of 2020 was $2.312 billion, with a year-on-year increase of +2%, mainly driven by the U.S. market. The Chinese market is still growing relatively, with a revenue of 923 million euros, with a year-on-year increase of +10%. Its covid-19 detection kit is the fast track diagnostics (FTD) sars-cov-2 analysis and detection kit

Perkin Elmer

steel, as the preferred material for body structural parts, is developing towards high strength. The revenue related to the COVID-19 in the second quarter was 196million US dollars. In this quarter, the organic revenue of diagnosis increased by 48%, and the organic revenue of exploration and analysis solutions business decreased by 10%. Non covid-19 sales naturally fell by 14% year-on-year, and non covid-19 diagnostic revenue fell by 20%

the novel coronavirus nucleic acid detection kit (RT-PCR) developed by the company was approved by the U.S. Food and Drug Administration (FDA) in March. Based on PCR detection, RNA extraction solutions and serology kits, the company has driven the sales of covid-19 related diagnostics. Each contributed more than $50million in revenue in the second quarter. Perkin Elmer is also actively studying other technologies for direct detection of covid-19, including instant testing and ELISA based antigen detection. The company is focusing on the simultaneous detection system of novel coronavirus and influenza, and hopes to commercialize the detection product before the beginning of the autumn flu season

list of the first half revenue of six domestic instrument enterprises

Mindray medical

in the first half of 2020, with the outbreak of COVID-19 worldwide, the demand for portable color Doppler ultrasound and mobile Dr of life information and support production line, ventilator, infusion pump and medical imaging production line has increased significantly, especially for life information and support production line. From the second quarter of 2020, the company began to export covid-19 antibody reagents to overseas markets, making up for some of the impact of the epidemic on the in vitro diagnostic production line

BGI

after the outbreak of COVID-19, BGI completed the research and development of a number of novel coronavirus detection kits at the first time. Its products include nucleic acid detection kits and antibody detection kits, and the technology covers fluorescent PCR, combined probe anchor polymerization sequencing, enzyme-linked immunosorbent assay and colloidal gold method. The relevant covid-19 test kit has obtained relevant qualifications and certifications from the European Union, the United States, Japan, Australia, Singapore, Canada and other countries and regions, and was the first to enter the WHO (World Health Organization) emergency use list. As of the end of the reporting period, BGI covid-19 test products have covered more than 180 countries and regions around the world, of which covid-19 nucleic acid test kits have been shipped overseas for a total of more than 35million people

Da'an gene

affected by the epidemic of novel coronavirus pneumonia, the market demand for novel coronavirus (2019 ncov) nucleic acid detection kits, nucleic acid detection instruments and related consumables increased significantly. The company made full efforts to produce and fully guaranteed market supply, which had a positive impact on the company's performance. The increase in business accumulation caused by the increase in operating income

Gaode infrared

epidemic prevention and control products: this epidemic fully reflects the importance of infrared thermal imaging products in the front line of epidemic prevention and control. As a key manufacturer of epidemic prevention and control materials designated by the Ministry of industry and information technology, the company fully guarantees the production of automatic infrared temperature detection and alarm system products, which are widely used in airports, railway stations, hospitals, subway stations, schools and other crowded public places in China; In overseas markets, with the gradual upgrading of epidemic prevention and control in various countries, the company has sold temperature detection and alarm system products to many overseas countries to meet their epidemic prevention needs

Wanfu biology

in the first half of 2020, with the global outbreak of COVID-19